Skip to main content
Erschienen in: Arthritis Research & Therapy 4/2003

01.12.2003 | Review

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

verfasst von: John D Hainsworth

Erschienen in: Arthritis Research & Therapy | Sonderheft 4/2003

Einloggen, um Zugang zu erhalten

Abstract

The chimeric anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B cell malignancies, and more recently it has emerged as a potential treatment for rheumatoid arthritis (RA), via selective B lymphocyte depletion. Experience in oncology shows that rituximab is well tolerated in a variety of settings, with mild-to-moderate infusion related reactions following the first infusion being the most common adverse event. Current data suggest that the safety profile of rituximab in patients with RA is similar to that in oncology, but that the adverse events are less frequent and less severe in patients with RA.
Literatur
1.
Zurück zum Zitat Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003, 63: 803-843.CrossRefPubMed Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003, 63: 803-843.CrossRefPubMed
3.
Zurück zum Zitat Zhang Z, Bridges SL: Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am. 2001, 27: 335-353.CrossRefPubMed Zhang Z, Bridges SL: Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am. 2001, 27: 335-353.CrossRefPubMed
4.
Zurück zum Zitat Edwards JCW, Cambridge G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001, 40: 205-211. 10.1093/rheumatology/40.2.205.CrossRefPubMed Edwards JCW, Cambridge G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001, 40: 205-211. 10.1093/rheumatology/40.2.205.CrossRefPubMed
5.
Zurück zum Zitat Leandro MJ, Edwards JC, Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002, 61: 883-888. 10.1136/ard.61.10.883.PubMedCentralCrossRefPubMed Leandro MJ, Edwards JC, Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002, 61: 883-888. 10.1136/ard.61.10.883.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Stahl H-D, Szczepaæski L, Szechiæski J, Filipowicz-Sosnowska A, Edwards JCW, Close DR, Stevens RM, Shaw TM: Rituximab in RA: efficacy and safety from a randomised, controlled trial [abstract]. Ann Rheum Dis. 2003, Suppl 1: 65- Stahl H-D, Szczepaæski L, Szechiæski J, Filipowicz-Sosnowska A, Edwards JCW, Close DR, Stevens RM, Shaw TM: Rituximab in RA: efficacy and safety from a randomised, controlled trial [abstract]. Ann Rheum Dis. 2003, Suppl 1: 65-
7.
Zurück zum Zitat Roche Products Ltd: Prescribing Information: Mab Thera. Welwyn Garden City, UK: Roche, 21 March 2002 Roche Products Ltd: Prescribing Information: Mab Thera. Welwyn Garden City, UK: Roche, 21 March 2002
8.
Zurück zum Zitat Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999, 10: 655-661. 10.1023/A:1008389119525.CrossRefPubMed Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999, 10: 655-661. 10.1023/A:1008389119525.CrossRefPubMed
9.
Zurück zum Zitat Ghielmini M, Schmitz SFH, Cogliatti S, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi , Vorobiof D, Cerny T: Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial [abstract]. Blood. 2002, 100: 604a- Ghielmini M, Schmitz SFH, Cogliatti S, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi , Vorobiof D, Cerny T: Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial [abstract]. Blood. 2002, 100: 604a-
10.
Zurück zum Zitat Hainsworth JD, Litchy S, Burris HA, Scullin DC, Corso SW, Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002, 20: 4261-4267. 10.1200/JCO.2002.08.674.CrossRefPubMed Hainsworth JD, Litchy S, Burris HA, Scullin DC, Corso SW, Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002, 20: 4261-4267. 10.1200/JCO.2002.08.674.CrossRefPubMed
11.
Zurück zum Zitat O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001, 19: 2165-2170.PubMed O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001, 19: 2165-2170.PubMed
12.
Zurück zum Zitat Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001, 19: 2153-2164.PubMed Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001, 19: 2153-2164.PubMed
13.
Zurück zum Zitat McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998, 16: 2825-2833.PubMed McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998, 16: 2825-2833.PubMed
14.
Zurück zum Zitat Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998, 92: 1927-1932.PubMed Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998, 92: 1927-1932.PubMed
15.
Zurück zum Zitat Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001, 97: 101-106. 10.1182/blood.V97.1.101.CrossRefPubMed Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001, 97: 101-106. 10.1182/blood.V97.1.101.CrossRefPubMed
16.
Zurück zum Zitat Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999, 17: 1851-1857.PubMed Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999, 17: 1851-1857.PubMed
17.
Zurück zum Zitat Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000, 18: 317-324.PubMed Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000, 18: 317-324.PubMed
18.
Zurück zum Zitat Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC, Bearden JD, Richards P, Greco FA: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000, 95: 3052-3056.PubMed Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC, Bearden JD, Richards P, Greco FA: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000, 95: 3052-3056.PubMed
19.
Zurück zum Zitat Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco GA: Single agent rituximab as first-line and maintenance therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003, 21: 1746-1751. 10.1200/JCO.2003.09.027.CrossRefPubMed Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco GA: Single agent rituximab as first-line and maintenance therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003, 21: 1746-1751. 10.1200/JCO.2003.09.027.CrossRefPubMed
20.
Zurück zum Zitat McLaughlin P, Hagemeister FB, Grillo-Lopez AJ: Rituximab in indolent lymphoma: the single agent pivotal trial. Semin Oncol. 1999, Suppl 14: 79-87. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ: Rituximab in indolent lymphoma: the single agent pivotal trial. Semin Oncol. 1999, Suppl 14: 79-87.
21.
Zurück zum Zitat Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M: Rituximab: ongoing and future clinical development. Semin Oncol. 2002, Suppl 2: 105-112. 10.1053/sonc.2002.30145.CrossRef Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M: Rituximab: ongoing and future clinical development. Semin Oncol. 2002, Suppl 2: 105-112. 10.1053/sonc.2002.30145.CrossRef
22.
Zurück zum Zitat Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000, 18: 3135-3143.PubMed Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000, 18: 3135-3143.PubMed
23.
Zurück zum Zitat Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Stahl H-D, Edwards JCW, Close DR, Stevens RM, Shaw TM: Infusions of rituximab in patients with rheumatoid arthritis are well tolerated [abstract]. Ann Rheum Dis. 2003, Suppl 1: 171- Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Stahl H-D, Edwards JCW, Close DR, Stevens RM, Shaw TM: Infusions of rituximab in patients with rheumatoid arthritis are well tolerated [abstract]. Ann Rheum Dis. 2003, Suppl 1: 171-
24.
Zurück zum Zitat Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997, 90: 2188-2195.PubMed Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997, 90: 2188-2195.PubMed
25.
Zurück zum Zitat Szechiński J, Szczepański L, Filipowicz-Sosnowska A, Stahl H-D, Edwards JCW, Close DR, Stevens RM, Shaw TM: Treatment of RA with rituximab leads to selective peripheral B-cell depletion with minimal effect on immunoglobulins [abstract]. Ann Rheum Dis. 2003, Suppl 1: 172- Szechiński J, Szczepański L, Filipowicz-Sosnowska A, Stahl H-D, Edwards JCW, Close DR, Stevens RM, Shaw TM: Treatment of RA with rituximab leads to selective peripheral B-cell depletion with minimal effect on immunoglobulins [abstract]. Ann Rheum Dis. 2003, Suppl 1: 172-
26.
Zurück zum Zitat Czuczman MS: Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol. 2002, Suppl 6: 11-17. 10.1053/sonc.2002.32748.CrossRef Czuczman MS: Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol. 2002, Suppl 6: 11-17. 10.1053/sonc.2002.32748.CrossRef
27.
Zurück zum Zitat Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001, 19: 389-397.PubMed Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001, 19: 389-397.PubMed
28.
Zurück zum Zitat Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA: Randomised phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and Leukaemia Group B 9712 (CALGB 9712). Blood. 2003, 101: 6-14. 10.1182/blood-2002-04-1258.CrossRefPubMed Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA: Randomised phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and Leukaemia Group B 9712 (CALGB 9712). Blood. 2003, 101: 6-14. 10.1182/blood-2002-04-1258.CrossRefPubMed
29.
Zurück zum Zitat Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346: 235-242. 10.1056/NEJMoa011795.CrossRefPubMed Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346: 235-242. 10.1056/NEJMoa011795.CrossRefPubMed
30.
Zurück zum Zitat Roche Registration Ltd: Summary of Product Characteristics: MabThera. Welwyn Garden City, UK: Roche, 2 June 1998 (revised 15 July) Roche Registration Ltd: Summary of Product Characteristics: MabThera. Welwyn Garden City, UK: Roche, 2 June 1998 (revised 15 July)
Metadaten
Titel
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
verfasst von
John D Hainsworth
Publikationsdatum
01.12.2003
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe Sonderheft 4/2003
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1008

Weitere Artikel der Sonderheft 4/2003

Arthritis Research & Therapy 4/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.